VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells
Authors
Keywords
Antibody fusion protein, Vascular endothelial growth factor receptor 2 (VEGFR2), MHC class I polypeptide-related sequence A (MICA), Immunosurveillance
Journal
IMMUNOLOGIC RESEARCH
Volume 64, Issue 4, Pages 1060-1070
Publisher
Springer Nature
Online
2016-05-06
DOI
10.1007/s12026-016-8800-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimal management for pediatric chronic myeloid leukemia
- (2016) Akihiko Tanizawa PEDIATRICS INTERNATIONAL
- Bosutinib for the treatment of chronic myeloid leukemia
- (2015) V. Doan et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- The interferon-alpha revival in CML
- (2015) Moshe Talpaz et al. ANNALS OF HEMATOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) Delphine Rea ANNALS OF HEMATOLOGY
- Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
- (2015) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity
- (2015) L. Kong et al. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
- Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
- (2015) Javid J. Moslehi et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015
- (2015) Philip A. Thompson et al. MAYO CLINIC PROCEEDINGS
- A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
- (2015) W. Deng et al. SCIENCE
- NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions
- (2015) YaJie Wang et al. Science China-Life Sciences
- NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
- (2015) Cinzia Fionda et al. Biomed Research International
- NKG2D Receptor and Its Ligands in Host Defense
- (2015) L. L. Lanier Cancer Immunology Research
- Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
- (2015) Stephan Klöss et al. Frontiers in Immunology
- Increased sMICA and TGFβ1levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells
- (2015) Stephan Klöß et al. OncoImmunology
- Soluble Ligands for the NKG2D Receptor Are Released during Endometriosis and Correlate with Disease Severity
- (2015) Iñaki González-Foruria et al. PLoS One
- Clinical and biological predictors of outcome following relapse of CML post-allo-SCT
- (2014) N A Jain et al. BONE MARROW TRANSPLANTATION
- Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2
- (2014) Wei Xie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MICA polymorphism: biology and importance in cancer
- (2014) D. Chen et al. CARCINOGENESIS
- Advances in Immunotherapy of Chronic Myeloid Leukemia CML
- (2013) Stefanie Erika Held et al. CURRENT CANCER DRUG TARGETS
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications
- (2013) G. Chitadze et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
- (2012) G. J. Ossenkoppele et al. BLOOD
- Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion
- (2011) Marco Mineo et al. ANGIOGENESIS
- Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands
- (2011) Beatriz Sanchez-Correa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia
- (2011) Izhar Hardan et al. CYTOKINE
- Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis
- (2011) Simona Taverna et al. INTERNATIONAL JOURNAL OF CANCER
- Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
- (2011) Frédéric Millot et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
- (2009) Janice M. Mehnert et al. HUMAN PATHOLOGY
- Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF
- (2009) Rossana Maffei et al. LEUKEMIA RESEARCH
- Prognostic significance of cellular vascular endothelial growth factor (VEGF) expression in the course of chronic myeloid leukaemia
- (2009) Ana Vidovic et al. Srpski Arhiv za Celokupno Lekarstvo
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started